Combining Daily and As-Needed PDE5 Inhibitors Is Not Recommended
You should not combine daily and as-needed PDE5 inhibitor therapy for erectile dysfunction because there is no evidence of added benefit, and doing so increases the risk of adverse events through excessive drug exposure and dose stacking.
The Core Problem: No Additional Efficacy with Increased Risk
The fundamental issue is pharmacologic redundancy. Both daily and as-needed PDE5 inhibitors work through the same mechanism—inhibiting phosphodiesterase type 5 to enhance cavernosal smooth muscle relaxation. Using both simultaneously doesn't provide synergistic benefit; it simply increases total drug exposure.
Evidence Against Combination Therapy
The 2018 AUA guidelines explicitly state that on-demand dosing versus daily dosing for tadalafil produces the same level of efficacy 1. This means you're not gaining additional erectile function by combining approaches—you're just increasing drug load in the system.
The most recent 2025 EAU guidelines make no mention of combining daily and as-needed PDE5 inhibitor regimens as a therapeutic strategy 2. This omission is telling: if combination therapy offered meaningful benefit, it would be included in evidence-based recommendations.
Safety Concerns: Adverse Events Follow a Dose-Response Pattern
The risk of adverse events increases with higher PDE5 inhibitor doses 1. Common side effects include:
- Dyspepsia
- Headache
- Flushing
- Back pain
- Nasal congestion
- Myalgia
- Visual disturbances
- Dizziness
When you combine daily and as-needed dosing, you're essentially creating a higher cumulative dose scenario, particularly if the as-needed dose is taken while daily medication is still in the system. This predictably increases adverse event rates without improving erectile function outcomes.
The Proper Approach: Choose One Strategy and Optimize It
Decision Algorithm:
For men with frequent sexual activity (≥2-3 times per week):
- Use daily low-dose tadalafil (2.5-5 mg)
- Provides continuous readiness without planning
- Maintains steady-state drug levels
For men with infrequent or unpredictable sexual activity:
- Use on-demand PDE5 inhibitors (sildenafil, vardenafil, avanafil, or tadalafil)
- Take before anticipated sexual activity
- Allows dose titration for optimal efficacy with minimal side effects
If initial strategy fails:
- First, verify correct medication use (sexual stimulation required, avoid large meals with some agents) 1
- Then titrate the dose upward within the same regimen 1
- Consider switching between different PDE5 inhibitors 3
- Only after optimizing monotherapy should you consider alternative treatments (vacuum devices, intracavernosal injections, penile prosthesis)
Common Pitfalls to Avoid
Don't stack medications thinking "more is better." The guidelines emphasize finding the optimal dose within a single regimen that balances efficacy with tolerability 1. This requires working with patients through dose titration, not adding another PDE5 inhibitor on top.
Don't confuse combination therapy with switching. If a patient doesn't respond to one PDE5 inhibitor, switching to a different agent is reasonable 3. But this means stopping the first medication, not adding the second one to it.
Special Circumstances Where Combination Makes Sense
The only evidence-supported combination involving PDE5 inhibitors is:
- PDE5 inhibitor + testosterone therapy in hypogonadal men 1
- PDE5 inhibitor + intracavernosal injections in select post-prostatectomy rehabilitation programs, though this requires careful monitoring for priapism 4
- PDE5 inhibitor + alpha-blockers for men with both ED and LUTS/BPH 5
These are different drug classes working through different mechanisms. Combining two PDE5 inhibitors (daily + as-needed) remains unsupported.
The Bottom Line
Select either daily or as-needed PDE5 inhibitor therapy based on sexual activity frequency, optimize the dose within that regimen, and only escalate to alternative treatments if monotherapy fails 2, 1. Combining both approaches offers no additional benefit while increasing adverse event risk and medication costs.